| Literature DB >> 33841553 |
Fahime Zavvari1,2, Sayed Mostafa Modarres Mousavi2,3, Maryam Ejlali1, Shahram Barfi4, Fariba Karimzadeh1.
Abstract
AMPA receptors, consisting of glutamate receptor type1 (GluR1) subunit are involved in the pathophysiology of some neurological disorders. In this study, the role of the GluR1 subunit in the development, as well as features of absence seizures were assessed. Both Wistar and WAG/Rij (a genetic animal model of absence epilepsy) rats with 2 and 6-month ages were included in the study. The expression of GluR1 was measured in the somatosensory cortex. Moreover, the effects of pharmacological activation and inhibition of AMPA receptors on the characteristic of absence epileptic activities were evaluated by microinjection of agonist or antagonist of AMPA receptors on the somatosensory cortex in the epileptic WAG/Rij rats. Distribution of the GluR1 subunit of AMPA receptors in the both IV (p < 0.001) and VI (p < 0.01) layers of the somatosensory cortex in the epileptic WAG/Rij rats was higher than non-epileptic animals. In addition, the microinjection of AMPA receptors agonist on the somatosensory cortex of the WAG/Rij rats increased both amplitude (p < 0.01) and duration (p < 0.001) of spike-wave discharges (SWDs), while injection of antagonist reduced amplitude (p < 0.001) and duration (p < 0.01) of SWDs in the somatosensory cortex of epileptic rats. The high expression of GluR1 in the somatosensory cortex of epileptic rats suggests the role of AMPA receptors consisting of the GluR1 subunit in the development of absence seizures. The modulatory effects AMPA receptors on the feature of SWDs suggest the potential of AMPA receptors antagonists as a therapeutic target for absence epilepsy.Entities:
Keywords: Brain; Epilepsy; Glutamate; Seizure; Somatosensory cortex
Year: 2020 PMID: 33841553 PMCID: PMC8019882 DOI: 10.22037/ijpr.2020.112638.13869
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Distribution of GluR1 in the somatosensory cortex of two- and six-month-old WAG/Rij and Wistar rats. (A) Photomicrographs of GluR1 distribution in the somatosensory cortex of two- and six-month-old WAG/Rij and Wistar rats. (B) The bar graph shows quantitative results of GluR1 distribution in the somatosensory cortex. GluR1 highly expressed in the both layers of somatosensory cortex in the 6-old-month WAG/Rij rats. ××× indicates p < 0.001 compared to Wistar rats. *** and ** indicate p < 0.01 and p < 0.001 respectively compared to 2-old-month WAG/Rij rats
Figure 2The effect of AMPARs agonist and antagonist on the SWDs. (A) ECoG traces were recorded before, during and after drug administration. (B and C) Bar charts summarized mean ± SEM of SWDs amplitudes and durations. Micro injection of agonist significantly increased the duration (p < 0.001) and amplitude (p < 0.01) of SWDs in comparison with before injection. Administration of AMPARs antagonist on the somatosensory cortex reduced the amplitude (p < 0.001) and duration (p < 0.01) of SWDs in comparison with before injection. In 2 h after injection (recovery time) the amplitude and duration of SWDs in agonist (p < 0.05 for amplitude and p < 0.001 for duration) and antagonist (p < 0.01 for amplitude and p < 0.05 for duration) groups has changed significantly compared to injection time and reached near the initial values